News

Otsuka Begins Paediatric MDR-TB Trials

Enrollment has begun for a ground-breaking clinical program exploring the use of delamanid in paediatric multidrug-resistant tuberculosis (MDR-TB). Otsuka is the first company to perform a trial among this population for regulatory approval. The programme will also evaluate the bioequivalence of a dispersible formulation for use with younger children and infants.

Childhood TB is a neglected segment of an already neglected disease. The WHO estimates that there are a half-million cases of childhood TB resulting in 64,000 deaths worldwide. In a recent report, the European Medicines Agency highlighted the success of paediatric regulation in spurring high-quality research, better information on the use of medicine in children and more age-appropriate formulations (www.ema.europa.eu/docs/en_GB/document_library/Other/2013/06/WC500143984.pdf).

A recommendation on the use of delamanid in adult MDR-TB patients is expected later this month from the European Committee for Medicinal Products for Human Use. The compound is also under regulatory review in Japan and a Phase 3 trial in adult MDR-TB patients is already underway, including those with co-existing HIV infection.

For more information, contact richard.ferreira@hkstrategies.com.

For more information on delamanid go to http://www.newtbdrugs.org/project.php?id=136.

More News
29 Nov 2018
On December 6, 2018, at 7AM EST, TREAT TB will host a capacity building webinar on community engagement in MDR-TB clinical trials. It will feature a presentation from Ezio Tavora dos Santos Filho, STREAM Community Engagement Coordinator from REDE-TB , followed by a question and answer session. The...
2 Oct 2018
The first ever U.N. General Assembly’s high-level meeting (UNHLM) on tuberculosis took place on Wednesday, September 26 in New York City. The U.N. delegation of countries agreed to ambitious targets including a commitment to finding 40 million undiagnosed cases of TB by the end of 2022 and...
18 Sep 2018
In an article written by Lucica Ditiu, Executive Director, Stop TB Partnership, and Jacqueline Huh, Head, Strategic Initiatives & Innovative Financing, Stop TB, the 'valleys of death' that hold back TB new tools innovation are discussed. These two valleys occur between new tool development and...